UCSF DIABETES, ENDOCRINOLOGY & METABOLISM TRAINING PROGRAM FACULTY RESEARCH SUMMARIES

My research is in oncogenesis and redifferentiation treatment for thyroid cancer and adrenal cancer. Thyroid and adrenal cancers are excellent models for cancer research because the different types of endocrine cancers vary in aggressiveness. We continue to study the genetic alterations that lead to cancer development using thyroid and adrenal cancers as models. My laboratory efforts are based at UCSF/Mt. Zion Medical Center, and I have close collaborations with Drs. Orlo Clark and Electron Kebebew. I am a Co-PI on projects including the Endocrine Tissue Bank, Endocrine Patient Database, Dedifferentiating Therapy for Thyroid Cancer, Gene Expression in Endocrine Disorder, and Cox-2 Fatty Acids and Thyroid Cancer.

Selected References

Hung CJ, Ginzinger DG, Zarnegar R, Kanauchi H, Wong MG, Kebebew E, Clark OH, Duh QY. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab. 2003 Aug;88(8):3694-9.

Kebebew E, Peng M, Treseler PA, Clark OH, Duh QY, Ginzinger D, Miner R. Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J Clin Endocrinol Metab. 2004 Dec;89(12):6105-11.

Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid. 2005 Mar;15(3):222-31.

back to faculty list